Baird raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $50 from $44 and keeps an Outperform rating on the shares. The firm said they reported a solid beat over expectations driven by Livmarli, leading them to raise FY2024 guidance above the top end of the previous range.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM: